Incyte Corp. is expanding its clinical collaboration with MedImmune, AstraZeneca’s global biologics research and development arm.
As part of the expanded agreement, the two companies will evaluate the effectiveness and safety of a combination therapy — featuring one product from each company — in treating patients with non-small cell lung cancer.
{iframe}https://www.bizjournals.com/philadelphia/news/2017/10/31/incyte-astrazeneca-lung-cancer-treatment-medimmune.html{/iframe}